Development and Validation of the Patient/Caregiver Reported Hydroxyurea Evaluation of Adherence for Life (HEAL) Scale

INTRODUCTION: Hydroxyurea reduces the incidence of vaso-occlusive episodes, stroke, and respiratory, cardiac, and renal damage in sickle cell disease by increasing fetal hemoglobin. However, because suboptimal adherence to hydroxyurea limits its effectiveness, understanding patient-specific barriers...

Descripción completa

Detalles Bibliográficos
Autores principales: Janson, Isaac A, Bloom, Ellen M, Hampton, Kisha C, Meier, Emily Riehm, Rampersad, Angeli G, Kronenberger, William G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749495/
https://www.ncbi.nlm.nih.gov/pubmed/36531301
http://dx.doi.org/10.2147/PPA.S387227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749495/
https://www.ncbi.nlm.nih.gov/pubmed/36531301
http://dx.doi.org/10.2147/PPA.S387227

Ejemplares similares